Iovance Biotherapeutics Inc (NASDAQ:IOVA) At $5.65: What To Do?

In last trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 6.62 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $5.65 trading at $0.09 or 1.62% at ring of the bell on the day assigns it a market valuation of $1.72B. That closing price of IOVA’s stock is at a discount of -224.42% from its 52-week high price of $18.33 and is indicating a premium of 10.62% from its 52-week low price of $5.05.

For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.27 in the current quarter.

Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information

Upright in the green during last session for gaining 1.62%, in the last five days IOVA remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $5.65 price level, adding 2.59% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -23.65% in year-to-date performance and have moved 6.81% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of -4.40% in past 30-days.

Wall Street analysts have assigned a consensus price target of 12.25 to the stock, which implies a rise of 53.88% to its current value. Analysts have been projecting 7.5 as a low price target for the stock while placing it at a high target of 17. It follows that stock’s current price would drop -32.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -32.74% for stock’s current value.

Iovance Biotherapeutics Inc (IOVA) estimates and forecasts

This year revenue growth is estimated to rise 13,568.39% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 72.17M for the same. And 9 analysts are in estimates of company making revenue of 86.48M in the next quarter. Company posted 482k and 715k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -8.25% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 31.48% while estimates for its earnings growth in next 5 years are of 45.45%.

Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders

VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.7478 of the company’s outstanding shares.

The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1052 of outstanding shares, having a total worth of $207.98 million.

On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 8.72 shares of worth $49.26 million or 2.86% of the total outstanding shares. The later fund manager was in possession of 7.13 shares on Nov 30, 2024 , making its stake of worth around $40.28 million in the company or a holder of 2.34% of company’s stock.